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Abstract
Background: Genomic deletions and duplications are important in the pathogenesis of diseases, such as
cancer and mental retardation, and have recently been shown to occur frequently in unaffected individuals
as polymorphisms. Affymetrix GeneChip whole genome sampling analysis (WGSA) combined with 100 K
single nucleotide polymorphism (SNP) genotyping arrays is one of several microarray-based approaches
that are now being used to detect such structural genomic changes. The popularity of this technology and
its associated open source data format have resulted in the development of an increasing number of
software packages for the analysis of copy number changes using these SNP arrays.
Results: We evaluated four publicly available software packages for high throughput copy number analysis
using synthetic and empirical 100 K SNP array data sets, the latter obtained from 107 mental retardation
(MR) patients and their unaffected parents and siblings. We evaluated the software with regards to overall
suitability for high-throughput 100 K SNP array data analysis, as well as effectiveness of normalization,
scaling with various reference sets and feature extraction, as well as true and false positive rates of
genomic copy number variant (CNV) detection.
Conclusion: We observed considerable variation among the numbers and types of candidate CNVs
detected by different analysis approaches, and found that multiple programs were needed to find all real
aberrations in our test set. The frequency of false positive deletions was substantial, but could be greatly
reduced by using the SNP genotype information to confirm loss of heterozygosity.
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Background
Chromosomal abnormalities frequently contribute to
human disorders including cancer [1-3] and mental retar-
dation (MR) [4-6], and characterization of these DNA
alterations is important for both diagnosis and under-
standing of disease mechanisms. A surprising recent find-
ing has been the extent to which genomic copy number
variants (CNVs) also exist in the normal population [7-
13]. Such variation may represent an important class of
mutations that predispose to disease.
Conventional cytogenetic studies such as karyotyping are
routinely used to detect genomic deletions and duplica-
tions involving more than 5–10 Mb, but detection of sub-
microscopic aberrations requires higher resolution
approaches. Oligonucleotide microarray technologies
offer high resolution, scalable methods for whole genome
screening and can detect previously unidentified CNVs
[6,14-17]. Among these approaches, the Affymetrix Gene-
Chip®  Mapping Assay [18,19] is increasingly used for
detecting CNVs in human DNA. This method involves a
whole genome sampling analysis (WGSA) combined with
high-density SNP genotyping oligonucleotide arrays. The
first such arrays contained 1,494 SNPs, and the subse-
quent 10 K arrays consisted of 11,555 SNPs [14]. Further
development resulted in the 100 K array set with probes
for 116,204 SNPs [16], and now the 500 K array set con-
taining 500,568 SNPs [18] is available. All these arrays can
be used to estimate copy number changes from probe
intensities, determine SNP genotypes by allele-specific
hybridization, confirm loss of heterozygosity, detect uni-
parental disomy, identify non-paternity and determine
haplotypes and parental origin of CNVs.
A number of software packages are available for analysis
of oligonucleotide arrays [14,20-23]. Three software pack-
ages, listed in Table 1, are currently in common use for
copy number analysis of Affymetrix 100 K SNP WGSA
data: Copy Number Analyser for GeneChip®  arrays
(CNAG) [22,24], DNA-Chip Analyzer (dChip) [23,25]
and Affymetrix GeneChip® Chromosome Copy Number
Analysis Tool (CNAT) [14,18]. All of these software pack-
ages perform normalization, scaling and feature extrac-
tion of signal intensities, and enable detection of copy
number alterations, but each package uses a different
algorithm for these functions. Briefly, CNAG normalizes
and scales the test sample against a "best-fit" user-defined
reference set and corrects the signal intensity ratios for the
differences in PCR product length and GC content. After
feature extraction a Hidden Markov Model (HMM) algo-
rithm is applied to infer copy numbers along each chro-
mosome [22]. dChip normalizes and scales data within
and between chips using a procedure established for
Affymetrix GeneChip® arrays [23], and then compares the
test sample to a user-defined reference set of samples to
estimate copy numbers in the test sample. This output is
then used by an HMM to infer copy numbers [23]. CNAT
compares a test sample to a reference set of 106 samples
provided by Affymetrix [18] or to a user-defined reference
set to estimate the copy number of each SNP locus, and
then applies a Kernel Smoothing algorithm to identify the
regions of copy number alteration [14]. The relative per-
formance of these methods in performing high through-
put oligonucleotide array normalization, scaling and
feature extraction and their performance in the sensitivity
or specificity of CNV detection have not previously been
reported, nor have the effects of different reference sets on
CNV discovery. Accordingly, in this study we compared
the performance of CNAG, dChip and CNAT software
(Table 1) using synthetic data and an empirical data set
that contains CNVs validated predominantly by fluores-
cent in situ hybridization (FISH). We report assessment of
the normalization, scaling and feature extraction algo-
rithms of these packages, as well as assessment of the
approaches used for identification of CNVs and their
boundaries. In addition, we tested the impact of reference
set size and composition on CNV detection with each
software package. Finally, we estimated the true and false
positive detection rates of these various approaches for the
identification of genomic gains or losses.
Results and discussion
The purpose of this study was to compare the perform-
ance of various software packages and the effect of differ-
ent reference sets on identification of CNVs in Affymetrix
100 K SNP array data. We performed the evaluations
described here using a synthetic data set and an empirical
data set that we generated from 331 individuals (Addi-
tional file 1). The sample set was derived from 107
patients with mental retardation (MR) and their unaf-
fected mothers and fathers, as well as 10 unaffected sib-
lings of the patients. Several of the individuals studied
have CNVs that were validated using independent meth-
ods [6].
We performed 100 K SNP WGSA experiments using 662
arrays of which 331 were Xba 50 K chips and 331 were
Hind 50 K chips (Additional file 1). From individual oli-
gonucleotide probe intensities, we determined the SNP
genotypes (Figure 1; Methods) and performed initial copy
number analysis using each of the software packages listed
in Table 1. Of the software packages we analyzed, only
those developed for Affymetrix GeneChip Mapping 100 K
arrays are capable of normalization, scaling and feature
extraction of Affymetrix data (Table 1). Hence, we used
CNAG, dChip or CNAT to perform this procedure on our
array data.
CNAG and dChip use HMM-based algorithms to detect
regions of genomic gains and losses and estimate theirBMC Bioinformatics 2007, 8:368 http://www.biomedcentral.com/1471-2105/8/368
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boundaries (Table 1). CNAT provides plots of copy
number and associated p-values along each chromosome,
but does not report CNVs or their boundaries. For the esti-
mation of CNVs and their breakpoints, we evaluated the
utility of CNAG, dChip and GLAD [26], the latter devel-
oped originally for array-CGH data analysis (Table 1).
Detection of candidate copy number variants from 
synthetic data
As an initial assessment of the software packages, we con-
structed a synthetic data set in which we purposely intro-
duced artificial CNVs, and then measured CNV detection
performance, including true and false positive detection
rates, of the software approaches.
Our data set contained 30 artificial normalized array
results produced from a normal individual's genome and
subsequent comparison to a reference set of 50 individu-
als (Methods). Normalization was performed using
CNAG, dChip and CNAT for these synthetic array results
(10 by each software). We then introduced 100 simulated
CNVs into each of the 30 synthetic samples with probe set
widths ranging from 5 to 23 and copy numbers ranging
from 0.3 to 3.0 (Methods). Detection of CNVs in these
normalized data was then performed using dChip and
GLAD (Methods). CNV detection could not be performed
using CNAG, because this software does not accept inter-
mediate stage normalized data as input.
The total numbers of putative CNVs detected from the
synthetic arrays, and assessments of false positive and
false negative rates are shown in Table 2. None of the soft-
ware detected all true CNVs as the true positive rates fell
between 0.23 (CNAT-GLAD, Hind data, Table 2) and 0.58
(CNAG-GLAD, Xba data, Table 2). All of the approaches
had false discovery rates ranging between 0 (CNAG-
GLAD, Hind data, Table 2) and 0.44 (dChip, Xba data,
Table 2). We observed generally superior performance in
the detection of deletions compared to the detection of
duplications. We found that dChip analysis of the syn-
thetic data resulted in the identification of the largest
number of putative CNVs but yielded fairly low true pos-
itive rates (0.32 and 0.26 for Xba and Hind data, respec-
tively) and the highest false discovery rates (0.44 and 0.42
for Xba and Hind data, respectively) (Table 2). In this
analysis the CNAG-GLAD approach showed the best over-
all true positive rates (0.58 and 0.42 for Xba and Hind
data, respectively) and lowest false discovery rates (0.009
and 0 for Xba and Hind data, respectively).
Detection of candidate copy number variants from 
empirical data
To assess the performance of the software approaches on
empirical data, we next analyzed 662 Affymetrix SNP
arrays, employing five approaches that in total used four
software packages (Figure 1, Table 3). To detect regions of
genomic gains and losses after normalization, scaling and
feature extraction by CNAG, dChip or CNAT, we applied
the HMM algorithms of CNAG and dChip, as well as the
adaptive weights smoothing (AWS) algorithm of GLAD
(Figure 1, Table 3). Due to the difference in normal X
chromosome copy numbers between males and females,
detection of X chromosome CNVs requires more complex
approaches than autosomal CNVs, and not all of the soft-
ware packages tested here were able to score genomic copy
number along the sex chromosomes. Hence, we focused
on copy number assessment of autosomal regions. To
identify a candidate CNV, we arbitrarily imposed a
requirement for at least four adjacent SNPs that demon-
strated a similar apparent gain or loss of copy number.
To determine the effect of reference set size and composi-
tion on CNV detection, we used four reference sets in our
analyses (Figure 1, Table 3). The algorithmic differences
Table 1: List of copy number analysis software packages evaluated
Developed for Affymetrix GeneChip Mapping 100 K Array Data Analysis
Software Name Normalization, scaling
and feature extractiona
Smoothing Estimation Reference
CNAG 1.1 Copy Number Analyser for GeneChip yes yes yes [22]
dChip (Nov 17, 2005) DNA-Chip Analyzer yes yes yes [23]
CNAT 3.0 Chromosome Copy Number Analysis Tool yes yes no [14]
Developed for Array CGH Data Analysis
Software Name Normalization, scaling
and feature extraction
Smoothing Estimation Reference
GLAD (R) Gain and Loss Analysis of DNA no yes yes [26]
aCapability to perform normalization, scaling and feature extraction on Affymetrix GeneChip® Mapping 100 K array data.BMC Bioinformatics 2007, 8:368 http://www.biomedcentral.com/1471-2105/8/368
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between CNAT, dChip and CNAG impose different
requirements with regards to the size range of the refer-
ence set used. However, by default, all of the software
packages we used assume that the reference set has a mean
copy number of 2.0 at all autosomal locations. A large ref-
erence set would usually satisfy this assumption because,
in such a set, rare polymorphic CNVs will have negligible
effects. A large reference set also provides the advantage of
reducing noise arising from the comparison. However,
common polymorphic CNVs in the reference sets could
still affect the results.
Pair wise comparisons of one sample to another can only
be performed with CNAG [22]. This may be useful in the
case of parent-offspring "trio" analyses, such as reported
in [6]. Direct comparison of array data derived from a
child to data derived from the parents is the most straight-
forward means of distinguishing de novo mutations from
inherited CNVs, and the boundaries of inherited aberra-
tions should usually be the same in the parent and child.
Thus, we tested CNAG, as well as CNAG normalization,
scaling and feature extraction combined with GLAD CNV
detection (CNAG-GLAD) using three pair-wise compari-
sons within each trio – child to father, child to mother,
Overview of the data analysis process Figure 1
Overview of the data analysis process. A) Methods appear in blue, and data in yellow. B) The reference sets used for each 
analysis method are as follows. '2': within each MR trio (child, mother and father), three comparisons were done – child to 
father as reference, child to mother as reference, and father to mother as reference. '50': each sample was compared to a ref-
erence set of 50 unaffected mothers of children with MR. These 50 mothers selected for this reference set had the lowest 
numbers of CNVs detected by dChip compared to other mothers. '214': each sample was compared to a reference set that 
included all 214 unaffected parents (107 mothers and 107 fathers) of the children with MR. '106': a default reference set of 106 
individuals provided by Affymetrix for copy number analysis with CNAT [18].
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Table 2: Candidate copy number variants from synthetic data
Total from Xba data
Methoda # CNVs # Duplications % #Deletions % # True CNVs # Unique True CNVsb True Positive 
Rate (power)c
# False 
Positive CNVs
False Discovery 
Rate
CNAG-GLAD 334 20 6 314 94 331 58 0.58 3 0.009
dChip 381 166 44 215 56 213 32 0.32 168 0.44
dChip-GLAD 70 0 0 70 100 70 31 0.31 0 0
CNAT-GLAD 111 10 9 101 90 101 36 0.36 10 0.09
Total from Hind data
Method # CNVs # Duplications % #Deletions % # True CNVs # Unique True CNVs True Positive 
Rate (Power)
# False 
Positive CNVs
False Discovery 
Rate
CNAG-GLAD 70 11 16 59 84 70 42 0.42 0 0
dChip 269 91 34 178 66 155 26 0.26 114 0.42
dChip-GLAD 101 5 5 96 95 94 33 0.33 7 0.07
CNAT-GLAD 49 0 0 49 100 48 23 0.23 1 0.02
aWhere two software packages are listed, the first one was used for normalization and the second for CNV detection.
bCNVs with different chromosomal locations and breakpoints.
cThe number of true (synthetic) CNVs per array is 100.BMC Bioinformatics 2007, 8:368 http://www.biomedcentral.com/1471-2105/8/368
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Table 3: Candidate copy number variants from empirical data
All from Xba data
Method Reference Set #CNVs # Duplications %a # Deletions %a # False Positive 
Deletionsb
%c
1-CNAG 2 3,210 1,755 55 1,455 45 970 67
2-CNAG 50 924 820 89 104 11 35 34
3-CNAG-GLAD 2 1,850 996 54 854 46 343 40
4-CNAG-GLAD 50 340 69 20 271 80 62 23
5-dChip 50 31,354 19,093 61 12,261 39 3,830 31
6-dChip 214 5,443 4,076 75 1,367 25 452 33
7-dChip-GLAD 50 1,292 66 5 1,226 95 456 37
8-dChip-GLAD 214 1,207 30 2 1,177 98 402 34
9-CNAT-GLAD 50 701 253 36 448 64 214 48
10-CNAT-GLAD 106 454 232 51 222 49 98 44
11-CNAT-GLAD 214 866 240 28 626 72 363 58
p <= 0.05 and copy number < 1.25 or > 2.75 from Xba data
Method Reference Set #CNVs # Duplications % # Deletions % # False Positive 
Deletions
%
1-CNAG 2 444 361 81 83 19 21 25
2-CNAG 50 235 211 90 24 10 3 13
3-CNAG-GLAD 2 416 332 80 84 20 27 32
4-CNAG-GLAD 50 133 48 36 85 64 17 20
5-dChip 50 17,034 4,846 28 12,188 72 3,804 31
6-dChip 214 2,273 907 40 1,366 60 452 33
7-dChip-GLAD 50 1,042 27 3 1,015 97 313 31
8-dChip-GLAD 214 1,027 22 2 1,005 98 283 28
9-CNAT-GLAD 50 426 87 20 339 80 115 34
10-CNAT-GLAD 106 272 88 32 184 68 61 33
11-CNAT-GLAD 214 540 117 22 423 78 172 41
All from Hind data
Method Reference Set #CNVs # Duplications % # Deletions % # False Positive 
Deletions
%
1-CNAG 2 2,127 1,161 55 966 45 638 66
2-CNAG 50 324 202 62 122 38 41 34
3-CNAG-GLAD 2 1,299 697 54 602 46 206 34
4-CNAG-GLAD 50 366 20 5 346 95 87 25
5-dChip 50 21,124 17,843 84 3,281 16 1,402 43
6-dChip 214 5,792 4,603 79 1,189 21 469 39
7-dChip-GLAD 50 790 42 5 748 95 253 34
8-dChip-GLAD 214 806 41 5 765 95 274 36
9-CNAT-GLAD 50 650 108 17 542 83 210 39
10-CNAT-GLAD 106 360 90 25 270 75 108 40
11-CNAT-GLAD 214 462 56 12 406 88 161 40
p <= 0.05 and copy number < 1.25 or > 2.75 from Hind data
Method Reference Set #CNVs # Duplications % # Deletions % # False Positive 
Deletions
%
1-CNAG 2 377 300 80 77 20 26 34
2-CNAG 50 52 12 23 40 77 15 38
3-CNAG-GLAD 2 383 287 75 96 25 29 30
4-CNAG-GLAD 50 140 9 6 131 94 38 29
5-dChip 50 6,488 3,230 50 3,258 50 1,392 43BMC Bioinformatics 2007, 8:368 http://www.biomedcentral.com/1471-2105/8/368
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6-dChip 214 1,822 637 35 1,185 65 468 39
7-dChip-GLAD 50 744 23 3 721 97 238 33
8-dChip-GLAD 214 748 18 2 730 98 245 34
9-CNAT-GLAD 50 547 52 10 495 90 182 37
10-CNAT-GLAD 106 311 67 22 244 78 89 36
11-CNAT-GLAD 214 426 48 11 378 89 150 40
aPercentage of all candidate CNVs.
bNumbers of false positive deletions were estimated using SNP genotype data (Methods).
cThis is the percentage of false positives among the deletions (# false positive deletions/# deletions * 100).
Table 3: Candidate copy number variants from empirical data (Continued)
and father to mother (Figure 1, Table 3, Methods). We
refer to this analysis within trios as a "reference set of 2".
dChip and CNAT require the use of larger reference sets:
the minimum sizes required are 10 for dChip [23] and 50
for CNAT [18]. So that one consistent reference set could
be used to compare the performance of all three software
packages, we chose a reference set of 50 unaffected moth-
ers of children with MR (Figure 1, Table 3, Methods).
These 50 mothers chosen were those with the fewest can-
didate CNVs identified by dChip, compared to the other
mothers in our data set (using a reference set of all 214
parents). With dChip and CNAT, it is possible to increase
the size of the reference set further, so we tested whether
this would be advantageous. For this purpose, we assem-
bled a reference set of 214 unaffected parents of children
with MR (Figure 1, Table 3, Methods). For CNAT, there is
a default reference set of 106 individuals provided by
Affymetrix, which was also evaluated (Figure 1, Table 3,
Methods).
The lists of candidate CNVs and their boundaries identi-
fied in the 331 samples by CNAG using reference sets of 2
and 50 individuals are shown in Additional files 2 and 3,
respectively. The CNVs detected with the CNAG-GLAD
approach are listed in Additional file 4 (reference set of 2)
and Additional file 5 (reference set of 50). Putative CNVs
found with dChip are shown in Additional files 6 and 7
(reference set of 50) and Additional file 8 (reference set of
214). CNVs detected by GLAD from the feature extracted
data by dChip (dChip-GLAD) are shown in Additional
file 9 (reference set of 50) and Additional file 10 (refer-
ence set of 214). Candidate CNVs identified using GLAD
from SNP copy number log2-ratios calculated by CNAT
(CNAT-GLAD) are listed in Additional file 11 (reference
set of 50), Additional file 12 (Affymetrix default reference
set of 106) and Additional file 13 (reference set of 214).
Table 3 summarizes the numbers of candidate genomic
deletions and duplications identified using each of these
combinations of methods and reference sets on the 331
individuals studied. The data are presented for the Xba
and Hind arrays separately, so a CNV that was identified
in a particular sample by both array types is listed under
both (Table 3). There is great variability in the numbers
and types of CNVs detected from the same sample set with
different analysis approaches. The fewest candidate CNVs
were detected using CNAG-GLAD and CNAG with the ref-
erence set of 50 – 340 from Xba and 324 from Hind data,
respectively (Table 3). The most putative CNVs were iden-
tified by dChip with the reference set of 50 – 31,354 from
Xba and 21,124 from Hind data (Table 3).
The types of candidate CNVs detected also varied greatly
among the 11 approaches. Duplications accounted for
between 2% and 89% of all CNVs (Table 3). The lowest
proportion of duplications, and thus the highest propor-
tion of deletions, was identified by dChip-GLAD. The
three highest proportions of duplications and lowest pro-
portions of deletions were detected by dChip with the ref-
erence sets of 50 and 214, and by CNAG with the
reference set of 50 (Table 3).
For three Hind and two Xba arrays, each from a different
sample, candidate CNVs were not detected by any
approach. Data from 97 Hind and 90 Xba chips predicted
30 or more putative CNVs by at least one method. How-
ever, none of the arrays had 30 or more aberrations
detected by all of the 11 approaches.
False positive rate
The ultimate approach to determining the false positive
rate of each copy number analysis method would be to
attempt validation of each candidate CNV using an inde-
pendent method. A subset of putative CNVs was con-
firmed using FISH (Table 4) [6], but it was not feasible to
do this for all of the many thousands of candidate CNVs
detected in this study (Table 3).
To obtain an estimate of false positive rates among a larger
number of candidate deletions, we used the SNP genotype
data, assuming that deletions (with copy number of 1 or
0) should not contain heterozygous genotype calls (Figure
1, Methods). The average proportion of false positive dele-
tions identified by SNP heterozygosity was 40%, ranging
from 23% to 67% in the Xba data, and between 25% and
66% in the Hind data (Table 3). In both array types, the
CNAG-GLAD combination with the reference set of 50
exhibited the lowest false positive deletion rate, and
CNAG with a reference set of size 2 produced the highest.B
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Table 4: Detection of validated CNVs
Sample 
ID
CNV Chr Length 
(kb)
CNAG 
Ref2a
CNAG 
Ref50
CNAG-GLAD 
Ref2
CNAG-GLAD 
Ref50
dChip 
Ref50
dChip 
Ref214
dChip-GLAD 
Ref50
dChip-GLAD 
Ref214
CNAT-GLAD 
Ref50
CNAT-GLAD 
Ref106
CNAT-GLAD 
Ref214
# Methods 
detected
% Methods 
detected
3476c delb 4 10,655 1 1 1 1 1 1 1 1 1 1 1 11 100
1895c del 13 4,887 1 1 1 1 1 1 1 1 1 1 1 11 100
4818c del 12 3,204 1 1 1 1 1 1 1 1 1 1 1 11 100
9143c del 11 3,175 1 1 1 1 1 1 1 1 1 1 1 11 100
8326c del 14 1,923 1 1 1 1 1 1 1 1 1 1 1 11 100
6235c del 10 1,737 1 1 1 1 1 1 0 1 0 1 1 9 82
6545c del 7 785 1 1 1 1 1 1 1 1 1 0 1 10 91
7807c del 22 731 1 1 1 1 1 1 1 1 1 1 1 11 100
4357c del 6 595 1 1 1 1 1 1 1 1 1 1 1 11 100
4357m del 6 595 1 1 1 1 1 1 1 1 1 1 1 11 100
4357c del 6 353 1 1 1 1 1 1 1 1 1 1 1 11 100
4357m del 6 353 1 1 1 1 1 1 1 1 1 1 1 11 100
5003c del 2 294 1 1 1 1 0 0 1 1 1 1 1 9 82
7551c del 2 220 1 1 1 1 1 1 1 1 1 1 1 11 100
7551m del 2 220 1 1 1 0 1 1 1 1 1 1 1 10 91
1280c del 4 192 1 1 1 1 1 0 1 1 1 0 1 9 82
1280m del 4 192 1 1 1 1 1 0 1 1 1 0 1 9 82
0674c del 2 147 1 1 1 1 0 0 1 1 1 1 1 9 82
0674f del 2 147 1 0 1 1 1 0 1 1 1 0 1 8 73
5566c del 14 130 0 0 1 1 0 0 0 0 1 0 1 4 36
6789c del 14 68 1 0 1 1 0 0 0 0 1 0 1 5 45
6789m del 14 68 1 0 1 1 0 0 0 0 0 0 1 4 36
3476c del 1 66 1 0 1 1 1 0 1 1 1 0 1 8 73
3476m del 1 66 1 0 1 0 0 0 1 1 1 0 1 6 55
6607c del 20 57 0 0 1 0 0 0 0 0 0 0 0 1 9
6607m del 20 57 0 0 1 0 0 0 0 0 0 0 0 1 9
8785c del 18 43 0 0 0 1 1 0 1 1 1 1 1 7 64
8785f del 18 43 0 0 0 0 1 0 1 1 0 0 0 3 27
9299f del 9 38 0 0 1 1 0 0 1 1 1 0 1 6 55
9299c del 9 38 0 0 1 1 0 0 1 0 1 0 1 5 45
8379c dup 10 23,842 1 1 1 1 1 1 1 1 1 1 1 11 100
4794c dup 16 3,356 1 1 1 0 1 1 0 0 0 0 0 5 45
8379c dup 15 1,481 1 1 1 1 1 1 1 1 1 0 1 10 91
3595c dup 15 781 1 1 1 0 1 1 0 0 1 0 1 7 64
3595m dup 15 781 0 1 0 0 0 0 0 0 0 0 1 2 18
3923c dup 11 494 1 1 0 1 1 1 0 0 1 0 1 7 64
3923m dup 11 494 0 0 0 0 1 1 0 0 0 0 0 2 18
6168c dup 17 324 1 0 1 0 1 1 0 0 0 0 0 4 36
Number of validated CNVs detected 29 24 33 28 27 21 26 26 29 17 32
% of validated CNVs detected 76 63 87 74 71 55 68 68 76 45 84
aDetection of CNV from at least one type of array data (Xba or Hind or both). 1 means detected, 0 means not detected.
bThe method of validation for each CNV is shown in Additional file 15.BMC Bioinformatics 2007, 8:368 http://www.biomedcentral.com/1471-2105/8/368
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We note that these false positive rates are likely underesti-
mates, especially for short CNVs, because stretches of
homozygous SNPs could also occur by chance in regions
with normal copy number.
The software packages tested here apply different algo-
rithms and statistics for CNV detection. We examined the
distribution of SNP copy numbers and found that they
showed the characteristics of a Gaussian distribution.
Thus, to assess and compare the significance of CNVs
detected by these different approaches, we performed a t-
test as follows. First, we calculated the log2-ratios of test
sample copy numbers versus reference copy numbers for
each SNP. Next we calculated the mean and standard devi-
ation (SD) of these log2-ratios within each candidate
CNV, and also for the rest of the same chromosome
excluding the region affected by the CNV. We then com-
pared these values using a t-test, and obtained the corre-
sponding p-values (Additional files 2,  3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13). We then filtered the candidate CNVs using
an uncorrected p <= 0.05 cutoff along with arbitrary copy
number value thresholds of <1.25 for deletions and >2.75
for duplications. The candidate CNVs that passed these
thresholds are summarized in Table 3. As expected, appli-
cation of these cutoff values resulted in fewer CNVs and
also reduced the false positive deletion rates in most
instances. However, the false positive deletion call rates
remained substantial, averaging 32%. Lower p-value
thresholds further reduced the numbers of candidate
CNVs, as expected (not shown). However, substantial
rates of false positive deletions still remained even with a
p <= 0.00001 cutoff, with an average false positive dele-
tion rate of 28%.
To assess how detection and false positive rates were
affected by the number of SNPs included in candidate
CNVs, we counted the number of candidates that
included at least 4, 11, 21, 41 or 101 SNPs (Figure 2). We
also calculated false positive deletion rates on the basis of
SNP heterozygosity at each level and applied p-value and
copy number thresholds as described above (Figure 2).
We note that the rate of false positive deletion calls in the
smallest size class (4–10 SNPs) may be unrealistically low
in our analysis, because homozygosity is more likely to
occur by chance over a few adjacent SNPs than over many.
However, there was a high number of CNVs that passed
our p-value (p <= 0.05) and copy number (<1.25 or
>2.75) thresholds and that were predicted by <= 10 SNPs,
indicating that many of the putative CNVs in this small
size range may be real. Interestingly, the false positive call
rate was often relatively high and the percentage of CNVs
that passed the p-value and copy number thresholds was
often relatively low in the largest CNV size class (>= 101
SNPs) compared to the other categories (Figure 2). The
majority of false positive CNVs in this size range exhibited
copy numbers that averaged only a little more or less than
2.0, but the change may have appeared significant because
of the large number of SNPs involved.
Candidate CNVs predicted by multiple methods
Putative CNV regions identified by at least two software/
reference set combinations from Xba or Hind data or both
from the same sample are presented in Additional file 14.
These regions were predicted by the software platforms
without applying additional filters based on p-value or
copy number thresholds. Because distinct approaches and
the two different chips in the 100 K set often detect
slightly different boundaries for a particular CNV, we
defined mutually predicted CNVs in this analysis as those
sharing at least 50% of the base pairs within a genomic
segment defined by the SNPs included in the deletion or
duplication.
Mutually predicted candidate CNVs consisting of fewer
than 50 consecutive SNPs are listed in Additional file 14A.
In this size range, a total of 8,649 putative CNVs consist-
ing of 5,418 duplications (63%) and 3,231 deletions
(37%) were detected in our sample set of 331 individuals
using two or more methods. 7,497 (86%) of these puta-
tive 8,649 CNVs (<50 SNPs) were detected by 2 distinct
software/reference set combinations, 919 (11%) by 3 or 4,
and 233 (3%) by 5 or more approaches. 1,512 of the can-
didate deletions predicted by more than one approach
(47% of 3,231) were considered to be false positive calls
on the basis of SNP heterozygosity (Methods, Figure 1).
Mutually predicted putative CNVs of 50 or more consecu-
tive SNPs are listed in Additional file 14B. A total of 1,084
such candidate CNVs were identified by at least two meth-
ods, including 926 duplications (85%) and 158 deletions
(15%). Of these larger CNVs, 963 (89%) were identified
by 2 distinct software/reference set combinations, 106
(10%) by 3 or 4, and 15 (1%) via 5 or more approaches.
154 (97% of 158) deletions predicted by more than one
approach were considered to be false positive calls on the
basis of SNP heterozygosity (Methods). We validated 3 of
the remaining candidate deletions using FISH (Additional
file 14, Table 4); the fourth one was not tested.
Rate of detection of confirmed CNVs
To determine the detection rate of real CNVs by each of
the software/reference set combinations, we assessed 38
CNVs (30 deletions and 8 duplications) that were con-
firmed by independent experimental approaches (Table 4,
Additional file 15) [6]. Some of these were inherited
CNVs that had been demonstrated in both the child and a
parent of one MR family. Other confirmed CNVs occurred
de novo in a child with MR and were shown not to be
present in either parent. SNP genotypes were used to con-
firm paternity in all cases.BMC Bioinformatics 2007, 8:368 http://www.biomedcentral.com/1471-2105/8/368
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Size distribution of candidate CNVs detected Figure 2
Size distribution of candidate CNVs detected. The five plots show numbers of candidate copy number gains and losses identi-
fied using Xba and Hind arrays, arranged according to the numbers of SNPs within the aberrations: A) all CNVs (>= 4 SNPs); 
B) CNVs >= 11 SNPs; C) CNVs >= 21 SNPs; D) CNVs >= 41 SNPs and E) CNVs >= 101 SNPs. The y-axis value of each hor-
izontal line represents the total number of CNVs detected by a given method: 1 – CNAG Ref2; 2 – CNAG Ref50; 3 – CNAG-
GLAD Ref2; 4 – CNAG-GLAD Ref50; 5 – dChip Ref50; 6 – dChip Ref214; 7 – dChip-GLAD Ref50; 8 – dChip-GLAD Ref214; 
9 – CNAT-GLAD Ref50; 10 – CNAT-GLAD Ref106; 11 – CNAT-GLAD Ref214 (the reference sets are described in Figure 1 
and in the Methods.) The left and right side of each panel correspond to the fraction of deletions and duplications, respectively. 
The orange bars within the black lines show the fraction of CNVs that passed the following confidence thresholds: p <= 0.05 
(t-test) and copy number < 1.25 for deletions (left); or p <= 0.05 (t-test) and copy number > 2.75 for duplications (right). The 
fractions of false positive deletion calls, calculated based on SNP heterozygosity, are indicated by the red vertical bars on the 
left side of each panel. For example, the y-axis value of the top line (5) in plot 'A' indicates the total number of candidate CNVs 
(52,478) including at least 4 consecutive SNPs identified by dChip Ref50 (from Xba and Hind data). 30% of the 52,478 putative 
CNVs were deletions (left) and 70% were duplications (right). 99% of the deletions (orange fraction of the line, left) and 22% of 
the duplications (orange fraction of the line, right) passed our p-value <= 0.05 and copy number (<1.25 or >2.75) thresholds 
described above. 34% of the candidate deletions were considered to be false positives, indicated by the red bar (left).BMC Bioinformatics 2007, 8:368 http://www.biomedcentral.com/1471-2105/8/368
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The confirmed deletions in this set all had a copy number
of 1 in the involved genomic region, and the confirmed
duplications all had a copy number of 3. Deletions of
~200 kb or larger were identified by most or all (between
9 and 11) of the 11 software/reference set combinations
used. As expected, detection rates were lower for smaller
deletions (Table 4). Successful detection of duplications
had lower rates overall (Table 4). Surprisingly, a rather
large 3.3 Mb duplication was detected by only 5 of the 11
software/reference set combinations (Table 4, Additional
file 15). Within this genomic segment, the average dis-
tance between SNPs was ~280 kb (Additional file 15),
which is substantially greater than the 23.6 kb average dis-
tance between SNPs across the whole genome in the 100
K array set [16].
No single method identified all 38 of the confirmed
CNVs. CNAG-GLAD with the reference set of 2 and CNAT-
GLAD with the reference set of 214 had the highest rates
for detection, identifying 33 and 32 of the 38 confirmed
CNVs, respectively (Table 4). Two large deletions were
divided by dChip and the CNAG-GLAD combined
approach into multiple smaller deletions (2–4 each),
instead of the single CNVs predicted by alternate
approaches (Additional file 15).
Candidate CNVs per individual
To estimate the average number of CNVs per genome in
our sample set, we chose a combination of three copy
number analysis approaches that resulted in optimal true
positive detection rate: CNAG-GLAD with the reference
set of 2, dChip with the reference set of 50 and CNAT-
GLAD with the reference set of 214. These three methods
together detected all of the 38 confirmed CNVs in this
study (Table 4, Additional file 15). We generated a list of
candidate CNVs that were identified by at least one of
these three approaches, from at least one array (Xba or
Hind). To reduce the false positive detection rate, we elim-
inated all of the putative aberrations that did not meet the
following criteria: p <= 0.05 (t-test); and copy number <=
1.25 (for deletions) or >= 2.75 (duplications). Deletions
considered false positive based on SNP heterozygosity
were also eliminated. We then calculated the average
numbers of remaining candidate CNVs per individual in
the 107 children with MR, and in the 224 unaffected par-
ents and siblings of the affected children.
In the 224 unaffected individuals we found an average of
39 candidate CNVs per genome, consisting of 20 dele-
tions and 19 duplications. The average size of the dele-
tions was 157 kb (in the range between 190 bp and 5.5
Mb), and the average size of the duplications was 244 kb
(ranging between 115 bp and 16.7 Mb). In the affected
children, the average number of candidate CNVs was 45,
including 26 deletions and 19 duplications. The average
size of the deletions was 191 kb (ranging between 220 bp
and 11.3 Mb), and the average size of the duplications was
208 kb (ranging between 220 bp and 23.8 Mb).
Theoretical resolving power
The ability to estimate genomic gains and losses and to
define their boundaries is dependent on the normaliza-
tion, scaling and feature extraction of the raw intensity
data. More effective normalization and feature extraction
yields higher signal-to-noise ratios, which enable superior
detection of regions with altered copy numbers. Using
SNP copy number data from the 30 validated deletions
and 8 confirmed duplications listed in Table 4, we calcu-
lated theoretical resolving powers of the normalization,
scaling and feature extraction algorithms used by CNAG,
dChip and CNAT with the various reference sets described
above (Figure 1B, Methods). We defined the resolving
power as the average size of the smallest single copy dele-
tion or duplication that could be detected at a given con-
fidence level. Mean test versus reference SNP copy number
log2-ratios were calculated from the data following feature
extraction, and they showed the characteristics of a Gaus-
sian distribution. The Welch t-test was then computed to
compare mean SNP copy number ratios within a given
CNV against the rest of the chromosome (Methods). For
this calculation, we assumed that SNPs were uniformly
distributed throughout the genome. We then estimated
the p-values that would be obtained for hemizygous dele-
tions (copy number 1) and single copy duplications (copy
number 3) containing increasing numbers of adjacent
SNPs using the means and standard deviations obtained
from 30 confirmed deletions and 8 confirmed duplica-
tions (Methods). In genomic regions where the SNP den-
sity is higher or lower than average, corresponding p-
values would be lower or higher than those presented in
Figure 3, but variation in SNP density would affect the p-
values across all of the methods similarly. Therefore, even
though absolute p-values change with SNP density, the
relative p-values presented here provide a valid compari-
son.
The resolving power calculated from the weighted average
of the 30 validated deletions (Table 4) is shown in Figure
3A. The resolving power calculated from the weighted
average of the 8 confirmed duplications (Table 4) is
shown in Figure 3B. We observed that the Affymetrix Map-
ping 50 K XbaI and HindIII assays had similar resolving
powers, so we combined the Xba and Hind data for these
analyses.
dChip normalization, scaling and feature extraction pro-
vided the highest resolving power for the deletions, with
negligible difference between the reference sets of 50 and
214 (Figure 3A). This result indicates that for any given p-
value cutoff, on average one would expect to be able toBMC Bioinformatics 2007, 8:368 http://www.biomedcentral.com/1471-2105/8/368
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detect the smallest one-copy deletions with dChip feature
extraction and our reference set of 50 or 214. Most other
methods showed only slightly decreased resolving power.
Reference set selection had little effect on resolving power
in most cases, although CNAT with the Affymetrix default
reference set of 106 ranked the lowest (Figure 3A).
Reference set selection had a greater effect on the resolving
power for duplications, and the reference sets chosen
from our own data set resulted in higher resolving power
than the Affymetrix default set of 106 individuals (Figure
3B). We note that our estimation of the resolving power
was probably less accurate for duplications than dele-
tions, since we had a smaller number of confirmed aber-
rations available for our analysis. Nevertheless, the
resolving power was clearly better for deletions than for
duplications, such that deletions of a given size could be
detected with higher confidence than duplications of the
same size.
Conclusion
We found that CNAG, dChip, CNAT and GLAD were suit-
able for high-throughput processing of Affymetrix 100 K
SNP array data for copy number analysis. Various refer-
ence sets selected from data produced by our research
team resulted in superior feature extraction, higher signal-
to-noise ratios, and higher rates of detection of confirmed
CNVs than the external default reference set provided by
Affymetrix. This difference may be due to experimental
variation between different laboratories, to differences in
the frequencies of SNP genotypes and copy number poly-
morphisms (CNPs) in ethnically diverse populations, or
to other unidentified factors. Therefore, we recommend
using a reference set, processed in the same laboratory and
ideally from samples with a similar ethnic composition to
the sample set.
We found considerable variation in the numbers of puta-
tive CNVs detected by various software/reference set com-
binations, and more CNVs were called by dChip than by
any other software tested. Rates of false positive deletion
calls identified by SNP heterozygosity were substantial
with all of the approaches tested, and the false positive
call rates did not correlate with the total number of candi-
date CNVs identified by a given approach. The highest rate
of false positive candidate deletion calls was produced by
CNAG using a reference set of 2 (within trios), but this is
likely, at least in part, due to the very small size of the ref-
erence set combined with noisy data. In such a small ref-
erence set, the average copy number may be quite
different from 2.0 in certain regions of the genome. For
example, similar results are expected using pair-wise test
versus reference comparisons for the very different cases of
a paternally inherited deletion (copy numbers 1, 1, and 2
in the child, father, and mother, respectively) and a dupli-
cation in the mother that was not inherited (copy num-
bers 2, 2, and 3, respectively) (Additional file 16). In such
cases, we accepted all possible CNVs as candidates for
optimal sensitivity (Methods, Additional file 16), but we
expected that a subset of these CNVs would be false posi-
tives.
Within a large reference set, the average copy number of
all loci is more likely to be close to 2.0, which improves
the confidence of CNV detection in a given sample. How-
ever, frequent polymorphisms in a large reference set may
skew the results. For example, a deletion affecting a single
genomic region occurring in 10% of the population could
decrease the mean of copy number in that region to 1.9 in
Theoretical resolving power of CNAG, dChip and CNAT  with reference sets of 2, 50, 106 and 214 (see Methods and  Figure 1 legend) Figure 3
Theoretical resolving power of CNAG, dChip and CNAT 
with reference sets of 2, 50, 106 and 214 (see Methods and 
Figure 1 legend). The resolving power was defined as the 
average size of the smallest one-copy deletion or duplication 
that could be detected with a given method at a given confi-
dence level. The theoretical p-value (in log10 scale) is shown 
as a function of the deletion (A) or duplication (B) size 
detected from Affymetrix GeneChip 100 K Xba and Hind 
data. For a given p-value, e.g. 10-5, the theoretical minimum 
size of detectable deletion or duplication is shown for each 
method. For a deletion or duplication of a given size, e.g. 
400,000 bp, the theoretical p-values are shown for each 
method.
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a large random reference set, while a deletion with 50%
frequency may push the base line to 1.5, resulting in a
false positive duplication call in a test sample that lacks
the aberration or a false negative deletion call in a test
sample that has the deletion. Data from a chromosomal
region rich in polymorphic sites might seem noisy and
might not yield distinguishable CNVs even though they
are frequent. Further understanding of CNVs and their fre-
quencies in the general population will help resolve this
issue and increase specificity of CNV detection in these
regions.
The performance of software packages in the detection of
single copy deletions was better than that of single copy
duplications. This may be due to the fact that deletions
produce a 2-fold change in copy number (from 2 to 1),
while duplications produce only a 1.5-fold change (from
2 to 3).
The rate of detection of confirmed CNVs (Table 4) was
independent of the total numbers of CNVs reported
(Table 3) by a particular software/reference set combina-
tion. As expected, larger CNVs were detected more consist-
ently than smaller ones, and the denser the SNP coverage
within a given chromosomal segment, the smaller the
CNVs (in bp) that could be detected with high confidence.
We found that CNAG-GLAD using pair wise comparisons
within trios (reference set of 2) detected the largest pro-
portion (87%) of the 38 validated aberrations, closely fol-
lowed by CNAT-GLAD with the reference set of 214
(84%) (Table 4). Unfortunately, these two approaches
also had the highest false positive deletion rates, of 66%
and 51%, respectively (Table 3). No single method
detected all of the confirmed CNVs, and each method
missed a different subset of variants. Thus, none of the
software/reference set combinations we tested appears to
be sufficient to detect all true CNVs, and several
approaches may need to be used together for efficient and
reliable copy number analysis of GeneChip SNP data. For
example, to maximize the detection rate of true positive
CNVs we recommend using the combination of CNAG-
GLAD with pair-wise comparisons of test and reference
samples, and the use of dChip and CNAT-GLAD with
large reference sets (>50). This combination of
approaches successfully detected all of the validated CNVs
in our study. To reduce false positive rates, we recommend
SNP genotype analysis of putative deletions (see Meth-
ods) and setting thresholds for statistical significance and
copy number values of putative CNVs.
We used the default parameter settings for copy number
analysis in each of the software packages evaluated in this
study, as would most users. We did not attempt a thor-
ough parameter optimization due to the large size of the
data set and the number of other variables under which
the software packages were tested. It should be noted
though that changing parameters for some of these soft-
ware packages may result in different numbers of putative
CNVs detected, and the optimal parameters for detection
of specific CNVs may also depend on the noise level of
each chip and the location and size of the CNVs. Among
the packages that we evaluated, there are no applicable
parameter settings to CNAT [14,18], and we used CNAT
only for normalization and feature extraction, not for
CNV detection. dChip automatically determines its opti-
mal HMM parameters for each chip from the raw data
[23], thus these parameters are not user accessible. GLAD
has a few adjustable parameters for AWS, such as the
lambda value for the number of breakpoints and a cluster-
ing parameter lambda [26]. We have examined the sensi-
tivity of CNV detection to AWS parameter change from
the default on a small subset of samples, and found that
the results did not change, even for the detection of our
smallest validated aberrations. CNAG's default HMM
parameters have been optimized by the software develop-
ers to detect full copy number changes (e.g. to 1 or 3) in a
mostly diploid sample [22,24]. These parameters are user
adjustable, and adjustment is specifically recommended
for non-diploid chromosomal regions or detection of
mosaic CNVs (with an average copy number change of
less than 1.0) (CNAG users' manual [24]). In some cases
one may wish to change these parameters to detect as
many true CNVs as possible, even though this would also
likely produce much higher false positive call rates. In
other circumstances, it may be more important to mini-
mize the false positive call rate, even if this means that
some real CNVs will be missed. Our study used exclusively
samples which are predominantly diploid, and so the
default parameters appear the most appropriate.
In addition to the results presented from the empirical
data set of 662 arrays, we have also tested the software on
a smaller synthetic data set with a higher number of sim-
ulated CNVs. Although the numbers of candidate CNVs
detected were not directly comparable to those found
from empirical data due to the differences between the
approaches, the following conclusions were consistent
between the empirical and simulation data. Software per-
formance in the detection of deletions was generally bet-
ter than that of duplications. dChip identified the most
putative CNVs from both the empirical and synthetic
data. However, it did not have the best true positive CNV
detection rate and had significant false positive rate in
both cases. On the synthetic data the CNAG-GLAD
approach yielded the best true positive CNV detection
rate.
The availability of both SNP genotypes and genomic copy
number information from the same data is a particularly
useful feature of Affymetrix GeneChip Mapping arrays.BMC Bioinformatics 2007, 8:368 http://www.biomedcentral.com/1471-2105/8/368
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The copy number analysis algorithms evaluated in this
paper all have substantial false positive candidate CNV
call rates; however, many putative deletions can be con-
firmed and a large proportion of false positives can be
eliminated without performing further experiments using
the genotype information. None of the copy number anal-
ysis programs tested here take genotype information into
account for identifying candidate deletions, and this
would be a useful feature for future implementation.
Allelic imbalance in heterozygous genotypes could also be
used in calling duplications, as it is in the recently
described CARAT algorithm [27].
Another recommendation for improvement of the soft-
ware packages we tested would be to assign statistical sig-
nificance to each CNV call and then use this information
to rank the candidate CNVs. None of the software pack-
ages we tested accurately describes the relative quality of
their CNV predictions. An independent statistical test,
such as the t-test we employed, is necessary to provide
confidence in the CNVs identified by various methods.
Furthermore, it would also be useful to rank candidate
CNVs by the deviation of copy number from 2.0. A
researcher could then decide approximately how many
false positive calls to tolerate to achieve the desired rate of
true CNV detection by setting the corresponding p-value
and copy number thresholds appropriately.
Using a combination of approaches described above to
optimize true positive detection rates and minimize false
positive rates, we estimated the average numbers of CNVs
per genome in our sample set. The average of 39 candidate
CNVs in unaffected individuals (20 deletions and 19
duplications) may be an overestimate, because a subset of
these may still be false positives. These numbers; however,
are in a range similar to those estimated by others in the
general population using different technologies and ana-
lytical approaches, reviewed by [12]. Many of the CNVs
we found in our sample set of 224 unaffected individuals
probably represent normal polymorphisms, and future
studies will characterize these candidate variants in more
detail.
In summary, hybridization data obtained from 100 K SNP
WGSA arrays can be used to identify single-copy constitu-
tional CNVs smaller than 200 kb. We found that detecting
all real CNVs from such data requires multiple computa-
tional approaches. The SNP genotype information that is
available for all samples analyzed with these arrays is use-
ful for recognizing many false positive calls and should be
used to improve the specificity of CNV detection. Further
improvement in the specificity of recognizing true CNVs
may be achieved without loss of sensitivity by better use
of the information provided by each of the individual 25-
mer oligonucleotide probes associated with each SNP on
the GeneChip arrays, by taking advantage of the increased
resolution of 500 K GeneChip arrays, and by further
improving the array design to provide more uniform cov-
erage of the genome.
Methods
Affymetrix GeneChip® 100 K Mapping Array data
For this analysis, we used a data set generated in a previ-
ous study [6] of families with children with mental retar-
dation (MR). The study group was composed of 107
children and both of their unaffected parents, plus 10
unaffected siblings of the affected children from 10 of the
families. DNA was isolated from 331 whole blood sam-
ples as described [6]. Hybridization to Affymetrix Gene-
Chip® 100 K Mapping arrays was performed according to
the manufacturer's recommendations (Affymetrix Gene-
Chip® Mapping 100 K Assay Manual; [18]) as previously
described [6].
Reference sets for copy number analysis
The reference sets described below were used for copy
number analysis of Affymetrix GeneChip® Mapping 100 K
array data:
• '2': three pair wise comparisons were performed within
each MR trio (child to father as reference, child to mother
as reference, and father to mother as reference). Deletions
and duplications in family members were called as
described in Additional file 16A.
• '50': each sample was compared to a reference set of 50
unaffected mothers of children with MR. These 50 moth-
ers selected for this reference set had the smallest numbers
of candidate CNVs identified by dChip, compared to the
other mothers in our data set (using a reference set of all
214 parents).
• '214': each sample was compared to a reference set com-
prised of all 214 normal parents (107 mothers and 107
fathers) of the children with MR.
• '106': a default reference set from 106 individuals pro-
vided by Affymetrix for copy number analysis with CNAT
[18].
Synthetic 100 K array data
We generated 30 artificial data sets by randomly shuffling
normalized 100 K SNP array data from a normal sample
with variability close to the median using the reference set
of '50' individuals. Input to the shuffling was normalized
copy number data from CNAG, dChip and CNAT, and 10
synthetic samples were produced for each of these soft-
ware packages. We then introduced 100 simulated CNVs
into each synthetic sample with SNP widths ranging from
5 to 23 and copy numbers ranging from 0.3 to 3.0. CNVBMC Bioinformatics 2007, 8:368 http://www.biomedcentral.com/1471-2105/8/368
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detection on these normalized data was then performed
by dChip and GLAD (this was not possible for the CNAG
HMM, since this software does not accept intermediate
stage normalized data).
Copy number analysis with CNAG and CNAG/GLAD
Detection of copy number variants was performed using
the Copy Number Analyser for GeneChip® arrays (CNAG)
Version 1.1 software [22], using the default parameters.
Each sample was compared to a reference set of 2 or 50
individuals. Regions of copy number gains or losses were
detected using the Hidden Markov Model (HMM) output
of CNAG. Deletions and duplications in individuals were
identified using the rules described in Additional file
16AA (for the reference set of 2) and B (for the reference
set of 50).
In addition to the CNAG HMM implementation, we also
identified copy number changes using the Gain and Loss
Analysis of DNA (GLAD) R package [26] with default set-
tings. Sample versus reference SNP copy number log2-
ratios calculated by CNAG were used as the input for the
CNAG/GLAD analysis.
Copy number analysis with dChip and dChip/GLAD
Genomic gains and losses were assessed against the refer-
ence sets of 50 or 214 individuals using the DNA-Chip
Analyzer (dChip) Version Release (Nov 17 2005) software
[23] with the default parameters. Regions of copy number
gain or loss in each comparison were detected using the
Hidden Markov Model (HMM) output of dChip.
We also detected copy number changes using the GLAD R
package [26] with the default settings instead of the dChip
HMM. SNP copy number log2-ratios of sample versus ref-
erence calculated by dChip served as the input for the
dChip/GLAD analysis. Deletions and duplications in
individuals were identified following the rules described
in Additional file 16B.
Copy number analysis with CNAT and GLAD
SNP copy numbers were determined using the Affymetrix
GeneChip® Chromosome Copy Number Analysis Tool
(CNAT) Version 3.0 [14,18] using the default parameters
and the reference sets of 50, 214 or 106 individuals. We
used the GLAD R package (Hupe et al. 2004) to identify
CNV boundaries from SNP copy number log2-ratios of
sample versus reference sample set calculated by CNAT.
Deletions and duplications in individuals were identified
using the rules described in Additional data file 16B.
Genotype analysis of deletions
SNP genotype calls were generated from probe signal
intensity data using the GeneChip® DNA Analysis Soft-
ware Version 3.0 (GDAS) [18], with a confidence score
threshold of 0.05 for genotype accuracy. We counted the
number of heterozygous SNPs within putative deletions
identified by each copy number analysis method
described above. If the rate of heterozygous SNPs was
more than 10% of the total SNP count within a candidate
deletion, the deletion was considered to be a false positive
call. If no more than 10% of SNPs were heterozygous, the
deletion was accepted. One reason for allowing up to 10%
heterozygous SNP call rate (instead of 0%) within dele-
tions was the occasional occurrence of errors in genotype
calls. Furthermore, although the presence of a deletion
may correctly be identified in a chromosomal segment by
a software package, the breakpoints may not be accurately
defined, resulting in the inclusion of heterozygous SNPs
from the normal region(s) flanking the deletion bounda-
ries. The percentage of heterozygous SNPs was below 10%
in all of our validated deletions. All candidate deletions
with more than 10% SNP heterozygosity that we
attempted to validate turned out to be false positives.
Validation of putative copy number variants (CNVs)
Validation of most putative CNVs was carried out by fluo-
rescent  in situ hybridization (FISH) on interphase and
metaphase chromosome spreads prepared according to
standard cytogenetic protocols, as described [6]. Bacterial
artificial chromosome (BAC) or fosmid inserts were used
as probes, selected via the University of California at Santa
Cruz (UCSC) genome browser [28,29], May 2004 human
genome assembly. A subset of CNVs were confirmed
using standard karyotyping, and one inherited deletion
was validated using quantitative PCR as previously
described [30].
Theoretical resolving power for detecting hemizygous 
deletions and duplications
We defined the resolving power as the average size of the
smallest one-copy deletion or duplication that could be
detected at a given confidence level. The confidence level
of finding hemizygous deletions (1 copy) or duplications
(3 copies) containing n  number of SNPs from feature
extracted copy number data by various methods was esti-
mated using the Welch t-test as follows. SNP copy number
log2-ratios of sample versus reference were calculated
from probe intensity values using CNAT, CNAG or dChip.
The means and standard deviations of these ratios were
calculated within each validated CNV, and in the rest of
the same chromosome outside the CNV that we used as
the control region. Assuming that the mean and standard
deviation of any 2 or more SNPs chosen from within the
CNV or control region would be equal (in keeping with a
Gaussian distribution), we compared the average log2-
ratios between n SNPs from the CNV with (c-n) SNPs
from the control region, where 'c'  represents the total
number of SNPs for that chromosome on the array. Using
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power for deletions and duplications were calculated
from combined Xba and Hind data using the average val-
ues of confirmed deletions and duplications, respectively,
and then by extrapolating to calculate p-values required to
detect a wide range of potential CNV sizes.
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